Scarica l'app Stockscreener
24.37
3.20%
-0.805
Dopo l'orario di chiusura:
24.21
-0.16
-0.66%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BEAM Giù?
Forum
Previsione
Beam Therapeutics Inc Borsa (BEAM) Ultime notizie
Beam Therapeutics at cantor conference: base editing lead comes into focus - Investing.com Canada
Cathie Wood’s ARK sells Alphabet stock, buys Meta and Beam Therapeutics - Investing.com
Beam Therapeutics at Citi summit: platform gains momentum across pipeline By Investing.com - Investing.com Canada
Transcript : Beam Therapeutics Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 01 - marketscreener.com
Why (BEAM) Price Action Is Critical for Tactical Trading - Stock Traders Daily
A Quick Look at Today's Ratings for Beam Therapeutics(BEAM.US), With a Forecast Between $35 to $80 - Moomoo
BEAM Stock Price, Quote & Chart - ChartMill
BEAM Reiterated by Wedbush -- Price Target Maintained at $65 - GuruFocus
BofA Securities Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $43 - Moomoo
BEAM Looks 14.6% Overvalued on GF Value™ - GuruFocus
Beam Therapeutics at Wells Fargo conference: base editing gains ground By Investing.com - Investing.com India
Beam drops after updating Phase 1/2 trial data for gene-editing drug - Seeking Alpha
3 Promising Genomics Stocks in the Spotlight in 2026 - TradingView
BEAM - Finviz
Beam Therapeutics Targets Accelerated FDA Approval for Base-Editing Treatment - Yahoo Finance
Beam Therapeutics reports BEAM-302 AATD trial update - grafa.com
BEAM Looks 26.9% Overvalued on GF Value™ - GuruFocus
A single dose pushed a protective protein above its threshold in Beam Therapeutics' trial - Stock Titan
BEAM Stock Price and Chart — NASDAQ:BEAM - TradingView
Beam Therapeutics appoints Eric Foster as CCO - The Pharma Letter
Beam Therapeutics names Eric Foster as chief commercial officer By Investing.com - Investing.com Nigeria
Beam Therapeutics names Eric Foster as chief commercial officer - Investing.com
Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer - Yahoo Finance
Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences - news.futunn.com
Three Beam Therapeutics talks will be webcast from Boston and New York - Stock Titan
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy - Investing.com
4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains - TradingView
Beam Therapeutics (NASDAQ:BEAM) Stock Price Down 6.2%Here's What Happened - MarketBeat
Beam (BEAM) Range: Posts a 1.62% Loss to $28.60 on the Day; Current Setup: $27.17 and $30.03 Define the Nearby Reference Levels in the Available RecordDebt Free Companies - Vinanet
Ultragenyx's gene therapy wins first FDA approval for rare metabolic disorder - Reuters
Beam (BEAM) Latest Quarter: EPS Falls Short of Its Estimate on the Day; Post-Earnings: The Stock Gains 9.41% in the Current UpdateRevenue Inflection Point - Vinanet
Beam (BEAM) Today: Adds 6.91% to Close at $28.41 on the Day; Range Check: Price Remains Between $26.99 Support and $29.83 Resistance in the Available RecordRVOL Spike - Vinanet
Beam Therapeutics (NASDAQ:BEAM) Shares Gap UpShould You Buy? - MarketBeat
Alphabet Inc. Purchases New Shares in Beam Therapeutics Inc. $BEAM - MarketBeat
Beam Therapeutics (BEAM) Edges Higher as Gene Editing Sector Draws Fresh AttentionCash Secured Put - Vinanet
Beam Therapeutics Inc. (NASDAQ:BEAM) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Beam Therapeutics (NASDAQ:BEAM) Downgraded by Wall Street Zen to "Strong Sell" - MarketBeat
Beam Therapeutics (BEAM): ARK Investment and Cathie Wood report 9.95% stake - Stock Titan
Farallon funds report 10.28M-share, 9.99% Beam Therapeutics (BEAM) position - Stock Titan
Equities Analysts Offer Predictions for BEAM Q3 Earnings - MarketBeat
Beam Therapeutics Inc (BEAM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy By Investing.com - Investing.com UK
Analyst Forecasts Just Became More Bearish On Beam Therapeutics Inc. (NASDAQ:BEAM) - simplywall.st
Weekly Recap: H1 2026 financials and BEAM-302 pivotal cohort dosing - TradingView
Beam Therapeutics Inc. $BEAM Shares Acquired by Janus Henderson Group PLC - MarketBeat
(BEAM) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Beam Therapeutics (NASDAQ:BEAM) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Analysts Have Lowered Expectations For Beam Therapeutics Inc. (NASDAQ:BEAM) After Its Latest Results - webull.com
H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80 - Moomoo
Beam Therapeutics Inc (BEAM) Stock News Today - TradingKey
First Trust Advisors LP Increases Stock Position in Beam Therapeutics Inc. $BEAM - MarketBeat
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):